Middle East Gene Therapy

Middle East Gene Therapy (MEGT) is a pioneering biotechnology company focused on addressing the high burden of rare genetic diseases in the Middle East and North Africa (MENA) region. The company leverages the unique genetic landscape of the region, characterized by high rates of consanguinity, to identify and develop gene therapies for recessive disorders that are often overlooked by global pharmaceutical firms. MEGT utilizes a proprietary AAV-based viral vector platform to deliver functional genes to patients, targeting metabolic, neurological, and ophthalmological conditions. By integrating local genomic data with cutting-edge therapeutic development, MEGT aims to establish a sustainable ecosystem for precision medicine in the Arab world. The company is led by prominent geneticists and is strategically positioned to lead clinical translation in the regional biotech sector.